肠易激综合征患者与无肠易激综合征者的粪便微生物组和代谢组差异及胆汁酸吸收不良的影响
该研究对80例肠易激综合征(IBS)患者和65名匹配对照者的粪便和尿液样本进行微生物组和代谢组分析,发现IBS患者与对照者相比,饮食与粪便微生物组之间的网络连接存在显著差异,且粪便代谢组谱可区分IBS患者与对照者。粪便代谢组而非微生物组可区分IBS患者中伴有与不伴有胆汁酸吸收不良(BAM)者。
要点
- IBS患者与对照者的粪便代谢组和尿液代谢组存在显著差异,且独立于症状亚型。
- 粪便代谢组可区分IBS患者中伴有与不伴有胆汁酸吸收不良(BAM)者。
- 粪便微生物组组成在IBS不同症状亚型间无显著差异。
核心结论
- IBS患者与对照者相比,尿液和粪便代谢组及粪便微生物组存在显著差异,且独立于IBS症状亚型。
- 粪便代谢组分析可用于区分IBS患者中伴有与不伴有胆汁酸吸收不良(BAM)者。
研究设计与样本
- 研究收集了80例IBS患者(符合Rome IV标准;16-70岁)和65名匹配的无IBS对照者的粪便和尿液样本,以及人体测量、医学和饮食信息。
- 对粪便进行鸟枪法和16S核糖体RNA扩增子测序,并通过气相色谱和液相色谱-质谱联用分析尿液和粪便代谢物。
- 通过保留放射性标记的硒-75同型胆酸牛磺酸来识别腹泻患者的胆汁酸吸收不良(BAM)。
主要发现
- 与对照者相比,IBS患者的饮食与粪便微生物组之间的网络连接存在显著差异,并伴随粪便代谢组的差异。
- 不同IBS症状亚型患者的粪便微生物群组成无显著差异。
- 粪便代谢组谱可区分IBS患者与对照者。
- IBS患者与对照者的尿液代谢组也存在显著差异,但大多数区分性代谢物与饮食或药物相关。
- 粪便代谢组(而非微生物组)可区分IBS患者中伴有与不伴有BAM者。
临床怎么用
- 粪便代谢组分析可能有助于区分IBS患者中伴有与不伴有胆汁酸吸收不良(BAM)者。
- 这些发现可能用于开发针对这些疾病的基于微生物的治疗方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is a heterogeneous disorder, but diagnoses and determination of subtypes are made based on symptoms. We profiled the fecal microbiomes of patients with and without IBS to identify biomarkers of this disorder. METHODS: We collected fecal and urine samples from 80 patients with IBS (Rome IV criteria; 16-70 years old) and 65 matched individuals without IBS (control individuals), along with anthropometric, medical, and dietary information. Shotgun and 16S ribosomal RNA amplicon sequencing were performed on feces, whereas urine and fecal metabolites were analyzed by gas chromatography and liquid chromatography-mass spectrometry. Co-occurrence networks were generated based on significant Spearman correlations between data. Bile acid malabsorption (BAM) was identified in patients with diarrhea by retention of radiolabeled selenium-75 homocholic acid taurine. RESULTS: Patients with IBS had significant differences in network connections between diet and fecal microbiomes compared with control individuals; these were accompanied by differences in fecal metabolomes. We did not find significant differences in fecal microbiota composition among patients with different IBS symptom subtypes. Fecal metabolome profiles could discriminate patients with IBS from control individuals. Urine metabolomes also differed significantly between patients with IBS and control individuals, but most discriminatory metabolites were related to diet or medications. Fecal metabolomes, but not microbiomes, could distinguish patients with IBS with vs those without BAM. CONCLUSIONS: Despite the heterogeneity of IBS, patients have significant differences in urine and fecal metabolomes and fecal microbiome vs control individuals, independent of symptom-based subtypes of IBS. Fecal metabolome analysis can be used to distinguish patients with IBS with vs those without BAM. These findings might be used for developing microbe-based treatments for these disorders.
引用
- Jeffery IB, Das A, O'Herlihy E, et al. Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption. Gastroenterology. 2019. PMID: 31843589. doi:10.1053/j.gastro.2019.11.301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。